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Abstract
Background: Human immunodeficiency virus-1 (HIV-1) has a minimal genome of only 9 genes,
which encode 15 proteins. HIV-1 thus depends on the human host for virtually every aspect of its
life cycle. The universal language of communication in biological systems, including between
pathogen and host, is via signal transduction pathways. The fundamental units of these pathways are
protein protein interactions. Understanding the functional significance of HIV-1, human
interactions requires viewing them in the context of human signal transduction pathways.
Results: Integration of HIV-1, human interactions with known signal transduction pathways indicates
that the majority of known human pathways have the potential to be effected through at least one
interaction with an HIV-1 protein at some point during the HIV-1 life cycle. For each pathway, we
define simple paths between start points (i.e. no edges going into a node) and end points (i.e. no edges
leaving a node). We then identify the paths that pass through human proteins that interact with HIV-1
proteins. We supplement the combined map with functional information, including which proteins are
known drug targets and which proteins contribute significantly to HIV-1 function as revealed by recent
siRNA screens. We find that there are often alternative paths starting and ending at the same proteins
but circumventing the intermediate steps disrupted by HIV-1.
Conclusion: A mapping of HIV-1, human interactions to human signal transduction pathways is
presented here to link interactions with functions. We proposed a new way of analyzing the virus
host interactions by identifying HIV-1 targets as well as alternative paths bypassing the HIV-1
targeted steps. This approach yields numerous experimentally testable hypotheses on how HIV-1
function may be compromised and human cellular function restored by pharmacological
approaches. We are making the full set of pathway analysis results available to the community.
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Human immunodeficiency virus-1 (HIV-1) is the causative
agent for acquired immune deficiency syndrome (AIDS), a
world-wide epidemic that according to statistics from the
world health organization has resulted in more than 2
million deaths; 33 million people are living with HIV,
including 2 million at the age of 15 years and under. While
current antiviral medication has dramatically improved the
life expectancy of AIDS patients, the medicines are not
available to everyone and drug resistance and side effects
are increasingly recognized problems. Thus, novel avenues
to anti-HIV-1 drug discovery are needed. The availability of
large-scale transcriptomic [1], proteomic [2-4] and pheno-
typic [5-7] information for HIV-1 provide an opportunity
to explore drug discovery through systems biology. Despite
the small genome of only 9 genes, which encode a slightly
larger number of proteins (15) due to post-translational
cleavage, more than 2500 interactions between human and
HIV-1 proteins have been reported in the literature [2-4,8].
This data has been recently used to create a human, HIV-1
interactome map via information integration of numerous
features such as gene expression, domain and motif
identification, tissue distribution, functional annotation,
subcellular localization and human network features and
HIV-1’s mimicry of human protein binding partners [9].
The general function of these interactions is for the virus to
subvert the human cellular machinery for its purposes.
Multiple mechanisms are employed by the virus, including
manipulation of endo- and exocytosis, nuclear transport,
transcription and translation, protein degradation and
autophagocytosis. In all cases the virus must communicate
with the host cell, and this communication typically takes
place through interactions between HIV-1 and human host
proteins. Communication through protein interaction is
the universal language of cells; chains of interactions
referred to as signal transduction pathways allow cells
to respond to the environment. The virus simply needs to
intercept these chains at one or more positions to “talk” to
the cell. To systematically generate viable hypotheses on
causal relationships between the phenotypic information
of which proteins are critical for virus function and the
protein interactions, a coherent picture of cellular pathways
has to be developed in which the position of the proteins
important for HIV-1 function are highlighted. Within this
global picture, it should be possible to identify the points
of interception by the virus through specific physical
interactions with human proteins. Towards this goal, we
recently presented an integration of the literature-reported
[3] and predicted [9] interaction maps with known signal
transduction pathway maps [10].
In this paper, we propose a novel approach to analyze
the HIV-1 intercepted pathways based on identification
of paths of connected interactions with directionality
within the pathways. The conceptual basis for the
approach is as follows. The major features of cellular
communication networks are their efficiency and robust-
ness brought about by the use of hubs and redundancy,
respectively. In contrast, the virus has to be a minimalist
in order to survive and will therefore target the hub
proteins, and this is what we (data not shown) and
others [11] have observed. Here, we propose the idea
that the redundancy may allow circumventing the points
of interception by HIV-1 (Figure 1). To lay the ground-
work for testing this hypothesis, for each pathway, we
define simple paths that start with a protein that does
not receive an input from another protein and end with a
protein that does not induce a change in any other
protein. Through this definition, the approach takes the
directionality of interactions in pathways into account.
We then identify which of these paths contain proteins
that interact with HIV-1 proteins, and find alternative
paths between the same start and end points that do not
traverse any protein that can interact with an HIV-1
protein. We supplement the combined map with
functional information, namely which proteins are
known drug targets and which proteins have shown an
effect on HIV-1 infectivity and other functions upon
siRNA silencing. The putative drug targets in the
alternative paths may be up-stream or down-stream of
the HIV-1 target, as we include all paths leading from
any valid input to any valid output node preserving the
directionality of the interactions. Using this approach,
we can generate experimentally testable hypotheses on
how HIV-1 survival may be compromised by pharma-
cological approaches providing a new resource to the
Figure 1
Schematic of the approach for analysis of HIV-1
targeted human signal transduction pathways.H I V - 1
interception of paths within cellular communication
pathways and alternative paths not involving any HIV-1
interactions leading to the same endpoints as the HIV-1
intercepted paths are shown.
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studies on human-pathogen interactions and HIV-1 drug
discovery.
Results and discussion
Many human signal transduction pathways
m a yb et a r g e t e db yH I V - 1
To identify HIV-1 targeted and alternative paths, we first
determined the intersection between the HIV-1, human
interactome and the gathered signal transduction pathways
[10]. This requires defining the interactome. We used the
following 5 definitions, all directly or indirectly derived
from the NIAID database [3]: Group 1 are the most likely
direct, physical known interactions based on reported
literature [3], while Group 2 refer to more likely indirect
interactions reported in the literature [3]. Group 1 and
Group 2 interactions are mutually exclusive. (For more
details on definition of Group 1 and Group 2, see [9]). In
an effort to define a more reliable set of known
interactions, we asked expert virologists to annotate the
interactions from the literature, primarily focusing on
Group 1 interactions. We found that many HIV-1
virologists do not trust the majority of the interactions
reported in the literature. Expert validated targets 1 refer to
those interactions where at least one expert annotated the
interaction as real. Expert validated targets 2 refer to those
interactions where all experts agree on their label. Finally,
we included all of our predicted interactions[9]. These
definitions vary in the degree of confidence that an
interaction in this category is real. While the Expert
validated targets 2 include the most confident interactions,
this dataset is also the smallest, leaving many false
negatives. On the other hand, Group 2 and the predicted
interactions contain many false positives. Thus, we have to
take into account that errors originating from uncertainty
in the experimental data will affect our analysis. Note that
we do not distinguish between interactions that are
obtained from high confidence experimental data such as
co-complex crystal structures as compared to more error-
prone experiments such as using in vitro pull-down assays.
An overview of the result of integrating these five
interaction networks with known signal transduction
pathways (see Methods) are shown for 453 pathways
analyzed in Figure 2. The graph shows the number of
interactions as a function of pathway, sorted by Group 1
interactions. The majority of known human pathways
can potentially be targeted through at least one Group 1
HIV-1, human protein interaction: 277 of 453 pathways
analyzed include at least one host factor that interacts
with one of the HIV-1 proteins, a number that increases
to 303 if predicted host factors are included. Some
pathways involve many interactions, but these are not
necessarily the largest pathways. Furthermore, some
pathways, even the very small ones, include expert
validated targets 2, indicating a very high confidence in
the interaction and its likely functional relevance.
T oo b t a i na ni n d i c a t i o na st ow h e t h e rt h e s ei n t e r a c t i o n s
are possible based on actual translation of the gene
transcripts, we investigated their presence in HIV-1
susceptible tissues (see Methods). The number of unique
proteins in all pathways combined is 3039. This
corresponds to 2956 genes, indicating that in the vast
majority of genes, it is only one isoform that has been
studied with respect to its interaction with HIV-1
proteins. This set of proteins gives rise to 15161 unique
HIV - UniProt pairs, out of which 689 are observed in
pathways. 396 of these pairs are targeted by HIV-1
according to group 1. Most of these interactions are
possible based on the expression of the human proteins
in HIV-1 susceptible tissues: of the 3039 proteins in the
pathways, only 85 are expressed in tissues that are not
susceptible to HIV-1, while 2728 are in tissues that are
susceptible to HIV-1 (for 175 there was no information
available and for 51 a corresponding gene could not be
identified). The information whether a gene is expressed
in a HIV-1 susceptible tissue is provided in Additional
File 1 for all pairwise interactions.
Human network redundancy provides numerous
alternative paths to the HIV-1 targeted paths
To analyze the integrated pathway maps, for each of the
453 pathways, we define simple paths that start with a
protein that does not receive an input from another protein
and end with a protein that does not induce a change in
any other protein. Searching for simple paths was carried
out by a breadth first search algorithm (see Methods).
Within these paths, we identify which contain proteins that
interact with HIV-1 proteins, and then find alternative
paths between the same start and end points that do not
traverse any protein that can interact with an HIV-1
protein. We supplement the combined map with func-
tional information, namely which proteins are known drug
targets [15] and which proteins have shown an effect on
HIV-1 infectivity and other functions upon siRNA silencing
[3-5]. This path search yields many potentially interesting
results. Table 1 lists example pathways, along with relevant
overall path and target statistics. The pathways shown are
top-ranked when sorting paths by the maximum number
of non-targeted paths that also contain siRNA genes. These
are particularly interesting pathways, because if a path that
does not contain a direct HIV-1 interaction partner is an
a l t e r n a t i v ep a t h ,t h ep r e s e n c eo fa ns i R N Ag e n ed e m o n -
strates that it is already functionally linked to HIV-1
biology, despite the absence of a direct HIV-1 partner. One
of these pathways, the generation of second messengers, is
illustrated in more detail in Figures 3 and 4. Figure 3 shows
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which it was downloaded [12]. Figure 4 shows a network
representation of the same pathway implemented using
cytoscape software [13], highlighting one of the HIV-1
targeted path satisfying our definition (see above) and the
positions of HIV-1, siRNA and drug targets in the network.
Table 2 lists the proteins in this pathway.
Degradation and down-regulation pathways are
highly targeted
Two of the top-most frequently HIV-1 targeted (according
to Group 1 definition) pathways are shown in Figure 5A
and 5B. These represent ranks 1 and 14 within the initial
plateau in Figure 2. Inspection of the lists of proteins in
thesepathways(seeAdditionalFile2)showsthatthereason
for the over-proportionally large fraction of HIV-1 targets in
these pathways is the proteasome and ubiquitin targets.
These can be observed in many pathways, especially the top
ranked ones in Figure 2. In graphs Figure 5A and 5B, the
proteasome (the most colored, large complex) is the
dominant feature. The graphs look very similar, although
one pathway was not specific for HIV-1 (ubiquitin-
dependent degradation of cyclin D1), while the other was
(Vif-mediated degradation of Apobec3g), demonstrating
that our analysis may reveal many more pathways targeted
by HIV-1 than those specifically already studied in the
Figure 2
Number of proteins targeted in signal transduction pathways by HIV-1. This graph represents the mapping of the
NCI PID [12] and Reactome [14] databases with respect to HIV-1 targets obtained from the NIAID database [2] and predicted
through information integration [8]. The pathways are sorted by the number of proteins known to interact with HIV-1 per
pathway, referred to as Group 1 targets (for details, see Methods). The data is compared to other definitions of HIV-1, human
protein pairs: Group 2 targets (more likely functional interactions from the NIAID database), predicted targets [8], Expert
validated targets 1 (where any expert annotated group 1 targets), Expert validated targets 2 (where all of the experts
annotated Group 1 targets with the same label, i.e. they all agreed that the interaction is real). We also plot the total number of
proteins in the pathway for comparison. Highlighted are the pathways that are discussed in this paper, with reference to their
rank according to the number of Group 1 targets, and the Figure in which they are illustrated.
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(page number not for citation purposes)Table 1: Overall path statistics on pathways. The table shows the top-ranked pathways from the NCI PID database [12] when sorting paths by the maximum number of non-
targeted paths that also contain siRNA genes after applying a filter to only include pathways with alternative paths that contain at least one HIV-1 target, at least one drug
target and at least one si-RNA target
Pathway Name Number
of end
points
Number
of paths
Non-
targeted
Number
of proteins
SiRNA Group 1 Group 2 Predicted Expert
validated
targets 1
Expert
validated
targets 2
Non-targeted
+ SiRNA genes
Number
of drug
targets
Activated AMPK stimulates
fatty acid oxidation in
muscle
61 7 1 6 51 11 1 0 0 4 2
1Generation of second
Messenger molecules
83 4 3 01 22 77 9 2 1 2 3
Phosphorylation of Emi1 3 10 8 4 1 1 2 2 0 0 2 1
Activation of BAD and
translocation to
mitochondria
283 71 1 74 0 0 1 2
Mitotic Prometaphase 2 4 2 78 12 4 5 10 1 0 1 1
Polo like kinase mediated
events
362 41 2 13 2 0 1 1
Notch HLH transcription 2 11 5 3 1 2 1 3 0 0 1 1
Global Genomic NER
GG NER
10 13 9 20 5 10 7 13 1 0 1 1
I n t r i n s i c P a t h w a y 2441 7 2 4 25 0 0 0 1 0
Orc1 removal from
Chromatin
3 11 1 57 13 43 0 54 1 1 0 8
…
2Cholesterol biosynthesis 7 140 140 8 1 0 0 1 0 0 7 2
3EGFR downregulation 12 88 5 17 4 6 4 11 3 1 0 4
1Ranked 177
th in Figure 2 and shown in Figures 3 and 4.
2Ranked 673
rd in Figure 2 and shown in Figure 6.
3Ranked 185
th in Figure 2 and shown in Figure 5C.
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)context of HIV-1 infection. Even when moving down the
ranks, other pathways are also related to degradation and
down-regulation. One example is the EGFR down-regula-
tion, shown in Figure 5C. Proteins in this pathway are listed
in Table 3. In this pathway, down-regulation is achieved via
internalizationofthereceptorfromthesurface.Thisanalysis
suggests removal of “unwanted” human cellular factors as a
major contributor to the disruption of human signaling
pathways by HIV-1.
Inhibiting cholesterol biosynthesis as a putative
mechanism to inhibit HIV-1
The pathways described above are those targeted most
extensively according to the Group 1 definition. To
Figure 3
Generationofsecondmessengerpathway. This image shows the pathway as it is illustrated in the Reactome Database [15].
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Generation of second messenger pathway. This is the same pathway as the one shown in Figure 3, but processed and
visualized using cytoscape software [17]. The network of interactions is shown and the proteins that are either targeted by
HIV-1, are an siRNA gene or are a drug target are highlighted in color: Purple - HIV-1 target according to Group 1; Blue -
siRNA gene; Red - drug target; Yellow - drug, si-RNA and HIV-1 target; Green - si-RNA and drug target; Silver - drug and HIV-
1 target; Brown - siRNA and HIV-1 target. Highlighted in green is one path leading from an input to an output node, and which
is intercepted by an HIV-1 interaction.
BMC Genomics 2009, 10(Suppl 3):S30 http://www.biomedcentral.com/1471-2164/10/S3/S30
Page 7 of 13
(page number not for citation purposes)Table 2: Proteins in generation of the second messenger molecules pathway. This table lists the proteins that are the constituents of
the generation of the second messengers pathway (Figure 3 and 4). Column 1 gives the uniprot identifier, column 2 the short gene
description, column 3 the gene symbol and column 4 highlights the features of this protein, including whether or not it is a HIV-1,
siRNA or drug target
Uniprot id Gene description Gene Symbol Properties
P07766 CD3e molecule epsilon (CD3-TCR complex) CD3E HIV-1 target according to Group 1, Group 2 and predictions,
known drug target
Q13094 lymphocyte cytosolic protein 2 (SH2 domain
containing leukocyte protein of 76kDa)
LCP2 HIV-1 target according to predictions, siRNA protein
P04234 CD3d molecule delta (CD3-TCR complex) CD3D HIV-1 target according to Group 1, Group 2 and predictions
P19174 phospholipase C gamma 1 PLCG1 HIV-1 target according to Group 2, and predictions
O43561 linker for activation of T cells LAT None
O75791 GRB2-related adaptor protein 2 GRAP2 None
P01730 CD4 molecule CD4 HIV-1 target according to Group 1, Group 2, predictions, and
experts, siRNA protein
P09693 CD3g molecule gamma (CD3-TCR complex) CD3G HIV-1 target according to Group 1, Group 2, and predictions
P43403 zeta-chain (TCR) associated protein kinase 70kDa ZAP70 HIV-1 target according to Group 1, Group 2, and predictions,
known drug target
Q08881 IL2-inducible T-cell kinase ITK Known drug target
P06239 lymphocyte-specific protein tyrosine kinase LCK HIV-1 target according to Group 1, Group 2, and predictions
P20963 CD247 molecule CD247 HIV-1 target according to Group 1, predictions and experts
Figure 5
Degradation and down-regulation pathways containing alternative paths to HIV-1 targeted paths.A .U b i q u i t i n
dependent degradation of cyclin D1. The colored circle represents the proteasome complex. B. Vif-mediated degradation of
Apobec3g. The same proteasome complex shown in A is part of this pathway also. This is an HIV-1 specific pathway as per its
listing in the pathway database, and thus already contains HIV-1 proteins as part of the pathway. C. EGFR down-regulation.
Here, down-regulation is achieved via internalization. The color coding is as follows: Purple - HIV target (according to G1,
except in the cholesterol one where the purple is according to predictions). Blue - si-RNA, Red - Drug Target, Yellow - All 3,
Green - si-RNA and Drug, Target, Silver - Drug Target and Group 1, Brown - siRNA and Group 1.
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novel HIV-1, human protein interactions, we selected the
cholesterol biosynthesis pathway, shown in Figure 6. The
proteins in this pathway are listed in Table 4. This
pathway is not targeted by any of the known interac-
tions, but according to our predictions [9], an HIV-1
protein (Tat) interacts with farnesyl-diphosphate farne-
syltransferase 1 (uniprot id P37268/gene symbol
FDFT1). The pathway contains two drug targets in
alternative paths, lanosterol synthase (2,3-oxidosqua-
lene-lanosterol cyclase, P48449/LSS) and squalene epox-
idase (Q14534/SQLE). It also contains a siRNA gene,
soluble 3-hydroxy-3-methylglutaryl-Coenzyme A
synthase 1 (Q01581/HMGCS1). Thus, the cholesterol
synthesis pathway would be a good candidate for drug
design because it contains alternative paths with known
drug targets and has already been functionally linked to
HIV-1 biology through the presence of the siRNA gene.
Additional evidence supporting such a functional link is
given by numerous statistics showing AIDS patients’
increased risk for arteriosclerosis. Furthermore, it was
shown experimentally, that the HIV-1 protein Nef blocks
the cholesterol efflux pump ABCA1, resulting in choles-
terol oil droplets inside cells [14]. Based on these
findings, it was previously proposed that activating
cholesterol efflux might counteract HIV-1. In the
Reactome and NCI pathway databases, ABCA1
appears in two pathways, (1) the RXR and RAR
heterodimerization with other nuclear receptor pathway
(from NCI), which is part of signaling by the Retinoic
Acid receptors pathway and (2) HDL mediated lipid
transport (from Reactome). Both pathways are targeted
by HIV-1, contain siRNA genes as well as numerous drug
targets (14 and 6, respectively) [for details see Supple-
mentary Table S2]. Thus, our analysis provides addi-
tional means to explore known HIV-1 interactions in the
context of different signaling pathways.
Cholesterol efflux and cholesterol synthesis are different
pathways, having in common that they link cholesterol
to HIV-1 pathogenesis. Thus, our pathway analysis
suggests that HIV-1 not only takes over control of
cholesterol concentrations inside cells, but also choles-
terol synthesis. This would not be surprising, since
cholesterol is needed for HIV-1 virion formation, dock-
ing and fusion. Thus, one novel anti-HIV-1 drug
treatment strategy suggested by our result would be to
inhibit cholesterol synthesis, and drugs to test this
hypothesis already exist (since the enzymes encoded by
the LSS and SQLE genes are known drug targets).
Conclusions and future work
We created a mapping of HIV-1, human interactions to
human signal transduction pathways to link interac-
tions with functions. We proposed a new way of
analyzing virus-host interactions by identifying HIV-1
Table 3: Proteins in EGFR downregulation pathway. This table lists the proteins that are the constituents of the EGFR downregulation
pathway (Figure 5D). Column 1 gives the uniprot identifier, column 2 the short gene description, column 3 the gene symbol and
column 4 highlights the features of this protein, including whether or not it is a HIV-1, siRNA or drug target
Uniprot id Gene description Gene Symbol Properties
O94973 adaptor-related protein complex 2 alpha 2 subunit AP2A2 HIV-1 target according to Group1, predictions and the
experts
Q96B97 SH3-domain kinase binding protein 1 SH3KBP1 HIV-1 target according to predictions
P09496 clathrin light chain (Lca) CLTA siRNA protein
P22681 Cas-Br-M (murine) ecotropic retroviral transforming
sequence
CBL HIV-1 target according to Group 2 and predictions
Q9UBC2 epidermal growth factor receptor pathway substrate
15-like 1
EPS15L1 None
P01133 epidermal growth factor (beta-urogastrone) EGF HIV-1 target according to Group 1 and predictions,
siRNA protein and known drug target
P62993 growth factor receptor-bound protein 2 GRB2 HIV-1 target according to Group 2 and predictions,
known drug target
Q00610 clathrin heavy chain (Hc) CLTC HIV-1 target according to Group 1 and predictions
Q9Y6I3 epsin 1 EPN1 None
O95782 adaptor-related protein complex 2 alpha 1 subunit AP2A1 HIV-1 target according to Group 1, predictions and experts
Q99962 SH3-domain GRB2-like 2 SH3GL2 None
P42566 epidermal growth factor receptor pathway substrate 15 EPS15 HIV-1 target according to predictions
P00533 epidermal growth factor receptor (erythroblastic
leukemia viral (v-erb-b) oncogene homolog avian)
EGFR HIV-1 target according to Group 2, and predictions,
siRNA protein and known drug target
O14964 hepatocyte growth factor-regulated tyrosine kinase
substrate
HGS HIV-1 target according to Group 2, siRNA protein
P60953 cell division cycle 42 (GTP binding protein 25 kDa) CDC42 HIV-1 target according to Group 1 and predictions
P62988 ribosomal protein S27a RPS27A HIV-1 target according to Group 1, predications and
experts, known drug target
O43597 sprouty homolog 2 (Drosophila) SPRY2 None
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paths bypassing the HIV-1 targeted steps in human
signal transduction pathways. Due to spatial and
temporal constraints, the fact that there is a human
host factor in a pathway does not necessarily imply that
this pathway is altered during infection. In particular,
the strength and lifetime of an interaction between a
human and an HIV-1 protein will determine what
pathways may really have an effect that is lasting and
transforming. Many proteins targeted by HIV-1 are hub
proteins with a high degree of interactions. These
interactions will not occur at the same time and in the
same complex composition, so the effect that the
interaction with the HIV-1 protein would have will
vary over time and with regulation of each respective
complex by posttranslational modifications, protein
activity and localization. Thus, taking the view that
interaction with an HIV-1 protein means that the signal
transduction pathway is targeted is clearly simplistic.
However, despite the use of these simplifying assump-
tions, the observation that a pathway contains a
putative HIV-1 binding partner at least provides us
with a testable hypothesis that HIV-1 interferes with
normal cellular functioning via the respective pathway.
Figure 6
Cholesterol biosynthesis pathway.T h ec o l o rc o d i n gi sa si nF i g u r e5 .
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pathways into account in the analysis. This would allow us
to study in detail where in the logical progression of a
pathway the HIV-1 targets are located so as to gage to what
extent putative drug targets are located up-or down-stream
of these targets. This may influence how pharmacologically
effective a treatment would be. For example, treatment
strategies based on downstream targets may have fewer
side-effects than up-stream targets. On the other hand, up-
stream targets may be more amenable to pharmacological
intervention, especially if they include cell surface recep-
tors. Other definitions of input and output nodes can also
be evaluated, such as linking them to molecular functions
such as receptors (input) and transcription factors (out-
put). Another approach could be to view the known drug
targets as putative input nodes. While these are many
viable future directions, using our current definition, the
approach already yields numerous experimentally testable
hypotheses on how HIV-1 function may be compromised
and human cellular function restored by pharmacological
approaches. We described some pathways in this paper,
such as the cholesterol biosynthesis pathway, and our
analysis provides proof-of-concept that we can find
druggable pathways that may hold promise for anti-HIV
drug discovery. There are many other pathways that may
hold equal or more promise for drug discovery and we
make available as a resource to the community the full set
of HIV-1 path and alternative path statistics on pathways,
as well as the lists of the points of HIV-1 interception of
pathways. This resource will allow researchers to investigate
these pathways in detail and derive complementary
approaches to understand the mechanisms of and circum-
vent HIV-1 takeover of the cell.
Methods
Pathway data
We have collected hundreds of pathways from the National
Cancer Institute (NCI) and Reactome protein pathway
databases [12,15]. At the time of down-loading (November
2008), the NCI Pathway Interaction Database (PID)
contained 83 hand-curated pathways containing nearly
5000 interactions. The Reactome database contained 823
hand-curated pathways and reported over 6000 interac-
tions. The two databases display significant overlap and
some pathways were merely textual descriptions of certain
processes with insufficient detail into the actual members
(proteins and small molecules) involved in the process. For
our analysis, we therefore removed pathways which were
complete subsets of other pathways and also removed
pathways which did not contain sufficient detail for our
experiments. The final dataset contained 453 pathways. For
some of the pathways, a relationship to HIV biology is
clear from the name, e.g. “HIV Nef pathway”, “Tat-
mediated elongation of the HIV-1 transcript”, “Vif-
mediated degradation of APOBEC3G”, and HIV-1 proteins
are listed as part of the pathways. We did not treat these
pathways differently from any other pathway in the
database only containing human proteins.
Interactions data
To determine the intersection between the HIV-1, human
interactome and the gathered signal transduction path-
ways, we need to define the interactome. We used the
following 5 definitions: Group 1 are the most likely
direct, physical known interactions based on reported
literature [3], while Group 2 refer to more likely indirect
interactions reported in the literature [3]. (For more
details on definition of Group 1 and Group 2, see [9]).
In a separate effort to define a better defined set of
known interactions, we asked expert virologists to
annotate the interactions from the literature. We found
that many HIV-1 virologists do not trust the majority of
the interactions reported in the literature. Expert
validated targets 1 refers to those interactions where at
least one expert annotated the interaction as real. Expert
validated targets 2 refers to those interactions where at
least two experts agree on their label. Finally, we
included all of our predicted interactions [9].
Path identification
For each pathway, we define simple paths that start with
a protein that does not receive an input from another
Table 4: Cholesterol biosynthesis pathway. This table lists the proteins that are the constituents of the cholesterol biosynthesis
pathway (Figure 5E). Column 1 gives the uniprot identifier, column 2 the short gene description, column 3 the gene symbol and column
4 highlights the features of this protein, including whether or not it is a HIV-1, siRNA or drug target
Uniprot id Gene description Gene Symbol Properties
Q01581 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) HMGCS1 siRNA protein
Q03426 mevalonate kinase MVK None
Q14534 squalene epoxidase SQLE Known drug target
P48449 lanosterol synthase (2 3-oxidosqualene-lanosterol cyclase) LSS Known drug target
Q15126 phosphomevalonate kinase PMVK None
P53602 mevalonate (diphospho) decarboxylase MVD None
O95749 geranylgeranyl diphosphate synthase 1 GGPS1 None
P37268 farnesyl-diphosphate farnesyltransferase 1 FDFT1 HIV-1 target according to predictions
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change in any other protein. Searching for simple paths in
signaltransductionpathwayswasaccomplishedasfollows.
Simple paths are those from a start node to an end node
which have no repeating vertices, where a start node is
defined as a node which has all its edges directed away
from it and an end node is defined as one which has all its
edges directed into it. The following example illustrates the
way paths are counted. Assume you have the pathway con-
sisting of interactions X Æ Y Æ Z, X Æ A Æ Z, B Æ A Æ Z,
C Æ D Æ E, where Y is the HIV-1 targeted protein.
According to our definition X, B, C are valid input nodes
andZ, E arevalidoutput nodes. Four isthetotalnumber of
paths in this pathway. Then, the paths containing the HIV-
1targetedproteinsareremoved.Countingagain,wewould
have 3 alternative paths left (namely X Æ A Æ Z, B Æ A Æ
Z, C Æ D Æ E). This number answers the question how
many of the complete paths (from a start node of the
originalgraphtoanendnodeoftheoriginalgraph)arestill
“active” after HIV-1 infection. These paths are referred to as
alternative paths throughout the text.
To find these simple paths in the full network graph of
each signal transduction pathway we use a breadth first
search algorithm [16], wherew eb e g i na tt h es t a r tn o d e s
and produce their children recursively until we reach the
end nodes, to find all the simple paths in the pathway
graph. One immediate problem with a breadth first
search is that it can get stuck in cycles (if a set of
interactions forms a directed cycle then a simple breadth
first search will not terminate). To handle this we
maintain a list of nodes that have been visited in the
particular simple path we are exploring and terminate if
we re-visit a node. This ensures that for example a simple
path with a simple cycle (a simple cycle is a cycle which
has the same start and end vertex but no other vertex in
the cycle repeats) will be explored as a single simple path
which ignores the cycle. We further proceed to find paths
that are not targeted by HIV-1 according to each of our
datasets (we look at all the paths from above and ignore
those that contain targeted proteins). We then identify
which of these paths contain proteins that interact with
HIV-1 proteins, and then find alternative paths between
the same start and end points that do not traverse any
protein that can interact with an HIV-1 protein.
Drug target, siRNA and tissue expression data
We supplement the combined map of signal transduc-
tion pathways with HIV-1, human protein interactions
with functional information, namely which proteins are
known drug targets [17,18] and which proteins have
shown an effect on HIV-1 infectivity and other functions
upon siRNA silencing [5-7]. The drug targets were
downloaded from DrugBank on May 1, 2009 [17,18].
All drug targets provided in the database were used,
which comprised 5463 proteins. The source of the siRNA
data was the three genome scale screens [5-7] and the
data were downloaded from the supplementary materi-
als. In each case, the final list of siRNA genes reported by
the authors was used. To identify whether a gene is
expressed in HIV-1 susceptible tissues or not, we
retrieved the tissues in which human proteins are
expressed from the Human Protein Reference Database
(HPRD) [19] and the Human Proteinpedia (HUPA)
website [20]. A total of 13920 human genes are
annotated with at least one tissue according to HPRD
and HUPA. The tissues susceptible to HIV-1 infection
were obtained from Levy et al. [21].
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